KMT2A is affected by gain‐of‐function mutations in various cancers and by chromosomal translocations leading to the formation of oncogenic fusion proteins in the so‐called KMT2A‐rearranged leukemias (KMT2A‐r), a distinct leukemia subtype. This evidence concerns the gene KMT2A and cancer.